Close Menu

NEW YORK (360Dx) – San Francisco-based Notable Labs today announced that it has raised $10 million in Series A funding, which it will put toward building its technology platform and team, as well as clinical feasibility studies related to blood cancers.

The firm provides a drug-testing service for oncologists identifying treatment options for blood-cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.